Ginkgo Bioworks Holdings, Inc. (DNA) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential · Updated May 1, 2026
Current Price
$10.32
Price Target
$7.84
Target Range
$4.35 — $12.00
Analyst Rating
Buy
Forward P/E—
Trailing P/E-1.8x
Forward PEG—
Implied Growth+21.5%
Median Target$7.50
Analyst Spread97.6%
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$4
-57.8%
Consensus
$8
-24.0%
Bull Case
$12
+16.3%
DNA Price Target Analysis
Updated May 8, 2026As of May 8, 2026, Ginkgo Bioworks Holdings, Inc. (DNA) has a Wall Street consensus price target of $7.84, based on estimates from 11 covering analysts. With the stock currently trading at $10.32, this represents a potential downside of -24.0%. The company has a market capitalization of $672M.
Analyst price targets range from a low of $4.35 to a high of $12.00, representing a 98% spread in expectations. The median target of $7.50 aligns closely with the consensus average. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 5 analysts rating the stock as a Buy or Strong Buy,2 rating it Hold, and 4 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, DNA trades at a trailing P/E of -1.8x. Analysts expect EPS to grow +21.5% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+178.5%
Avg Forward P/E18.9x
Peers with Coverage10 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 BEAMBeam Therapeutics Inc. | $3.2B | $31.47 | $40.83 | +29.7% | Buy | — | 27 |
 TWSTTwist Bioscience Corporation | $3.6B | $58.54 | $49.50 | -15.4% | Buy | — | 13 |
 SRPTSarepta Therapeutics, Inc. | $2.2B | $20.80 | $24.63 | +18.4% | Buy | 6.9x | 54 |
 CDNACareDx, Inc | $1.1B | $21.44 | $24.00 | +11.9% | Buy | 22.8x | 13 |
 CRSPCRISPR Therapeutics AG | $5.1B | $52.42 | $63.00 | +20.2% | Buy | — | 38 |
 NTLAIntellia Therapeutics, Inc. | $1.6B | $13.71 | $20.88 | +52.3% | Buy | — | 39 |
 EDITEditas Medicine, Inc. | $297M | $3.03 | $6.00 | +98.0% | Buy | — | 25 |
 FATEFate Therapeutics, Inc. | $280M | $2.43 | $39.50 | +1525.5% | Buy | — | 31 |
 ILMNIllumina, Inc. | $21.1B | $138.71 | $147.38 | +6.3% | Buy | 26.8x | 50 |
 TMOThermo Fisher Scientific Inc. | $176.4B | $474.56 | $654.67 | +38.0% | Buy | 19.1x | 42 |
Upside Potential Comparison
FATEEDITNTLATMOBEAMCRSPSRPTCDNASee DNA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs DNA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare DNA vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonDNA — Frequently Asked Questions
Quick answers to the most common questions about buying DNA stock.
What is the DNA stock price target for 2026?
DNA's consensus price target is $7.84, -24.0% below the current price of $10.32. The 11 analysts tracking DNA see downside risk at present valuations.
Is DNA a buy, sell, or hold?
DNA has a consensus rating of "Buy" based on 11 Wall Street analysts. The rating breakdown is mixed, with 2 Hold ratings making up the largest segment. The consensus 12-month price target of $7.84 implies -24.0% downside from current levels.
Is DNA stock overvalued or undervalued?
DNA's current price is $10.32 with a consensus target of $7.84 (-24.0% implied move). Analyst estimates suggest the stock is overvalued at current levels.
How high can DNA stock go?
The most bullish Wall Street analyst has a price target of $12 for DNA, while the most conservative target is $4.35. The consensus of $7.84 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover DNA stock?
DNA is moderately covered, with 11 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 5 have Buy ratings, 2 recommend Hold, and 4 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the DNA stock forecast?
The 12-month DNA stock forecast based on 11 Wall Street analysts shows a consensus price target of $7.84, with estimates ranging from $4.35 (bear case) to $12 (bull case). The median consensus rating is "Buy".
Should I buy DNA stock?
Analysts are cautious on DNA, with 4 Sell ratings and a price target of $7.84 (-24.0% from current price). The "Buy" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do DNA price targets vary so much?
DNA analyst price targets range from $4.35 to $12, a 98% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $7.84 consensus represents the middle ground.